{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01142050",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Cellonis-CR-2.3"
      },
      "Organization": {
        "OrgFullName": "Cellonis Biotechnology Co. Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Stem Cell Therapy for Type 2 Diabetes Mellitus",
      "OfficialTitle": "A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2010",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 2011",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2011",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 10, 2010",
      "StudyFirstSubmitQCDate": "June 10, 2010",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 11, 2010",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 10, 2010",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 11, 2010",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Cellonis Biotechnology Co. Ltd.",
        "ResponsiblePartyOldOrganization": "others"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Cellonis Biotechnology Co. Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "The purpose of the study is to evaluate the efficacy and safety in the treatment of Insulin Resistance of Type 2 Diabetes Mellitus with Bone Marrow Mesenchymal Stem Cells.",
      "DetailedDescription": "To evaluate the feasibility and safety of transplantation treatment using umbilical cord mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing insulin injection treatments.\nTo assess efficacy of transplantation treatment using umbilical cord mesenchymal stem cells in patients with type 2 diabetes mellitus."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Type 2 Diabetes Mellitus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "stem cells;",
          "diabetes mellitus;",
          "treatment."
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "24",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "mesenchymal stem cells",
            "InterventionDescription": "1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously."
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;",
            "PrimaryOutcomeDescription": "Insulin resistance index indicated by ITT change compared with baseline.\nRate of reducing exogenous insulin requirement and OGLD dosage compared with baseline.\nHemoglobin A1c.\nFast blood glucose (FBG) and Postmeal blood glucose (PBG).\nC-peptide levels.\nSerum Insulin levels.",
            "PrimaryOutcomeTimeFrame": "one year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Serious adverse event frequency and severity",
            "SecondaryOutcomeTimeFrame": "one year"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nFree will taking part in the study and ability to provide written informed consent;\nType 2 diabetes mellitus (as guideline WHO, 1999);\nAge 18-75 years old，Male/Female;\n19≤Body mass index (BMI)≤30㎏/㎡;\nFast blood glucose (FBG)≥7.0 mmol/L, and HbAc1≥7％;\nIntravenous insulin tolerance test（ITT）indicate patient being insulin resistance;\nNot pregnant or nursing;\nNegative pregnancy test;\nFertile patients will use effective contraception.\n\nExclusion Criteria:\n\nSevere concurrent medical condition (e.g., serious heart disease, lung disease, or hematopoietic dysfunction, or liver dysfunction, or kidney dysfunction);\nActive infection requiring treatment;\nUnexplained febrile illness;\nKnown immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Armed Police General Hospital, P.R. China",
            "LocationCity": "Beijing",
            "LocationZip": "100085",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Shi X Y, M.D.",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003920",
            "ConditionMeshTerm": "Diabetes Mellitus"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafAsFound": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9522",
            "ConditionBrowseLeafName": "Insulin Resistance",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M21707",
            "InterventionBrowseLeafName": "Pancrelipase",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9517",
            "InterventionBrowseLeafName": "Insulin",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M172956",
            "InterventionBrowseLeafName": "Insulin, Globin Zinc",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M12266",
            "InterventionBrowseLeafName": "Pancreatin",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Gast",
            "InterventionBrowseBranchName": "Gastrointestinal Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          }
        ]
      }
    }
  }
}